Ruben Argueta

Ruben Argueta has over 25 years of life science experience, blending Finance, Laboratory Operations, Communications, Investor Relations, and Board Relations. Recently, he served as Chief Operating Officer at RadioEye, Inc., a healthcare AI startup. In 2022, Ruben served as Vice President & Chief of Staff to the CEO of QuidelOrtho Corporation, a Fortune 500 company, where he focused on executive and organizational alignment, delivering powerful results to M&A Integration, Business Transformation, and Board Relations.

Prior to that, he served as Quidel Corporation’s Chief of Staff and Director of Investor Relations, where he built the company’s highly regarded Investor Relations function, leading it for over 10 years, including through a high-growth phase that saw a compounded annual growth rate of 28% over 12 years. Early on, Ruben changed Quidel’s investment perception – from a boom-or-bust binary trade – to a compelling, long-term growth investment with multiple growth catalysts, which resulted in a majority of supportive, long-only shareholders. Notably, he also led the Investor Relations and Communications functions through the pandemic, as Quidel developed and launched the first rapid antigen COVID-19 diagnostic product for the US market.

Ruben was a key driver behind several transformative acquisitions, including the acquisition of Ortho Clinical Diagnostics, Inc. by Quidel, leading a media and shareholder campaign as well as communicating with regulatory agencies to approve the $6B deal. He also played a leading role in Quidel’s acquisition of the Alere assets for $680M.

Prior to the role, Mr. Argueta led other M&A activities, including integration, and held various strategic and laboratory operational leadership roles at Quidel and Santa Cruz Biotechnology, Inc. Mr. Argueta earned an M.B.A. in Global Management from the University of Phoenix, and a B.A. in Biology from the University of California at Santa Cruz.